- Insurance rollout shows pharmacies and NACDS in action
- NACDS RxImpact shines spotlight on pharmacists' increasing role in delivery of healthcare services
- FDA approves liquid form of Merck HIV drug Isentress for infants, small children
- Axe aims for world peace with Axe Peace, campaign
- Industry players join Blue Button initiative
WHITEHOUSE STATION, N.J. — Drug maker Merck has completed its acquisition of eye care company Inspire.
As previously reported, Merck announced its plan to acquire the company for $5 per share in cash, or $430 million. In addition, Monarch Transaction, a wholly-owned subsidiary of Merck, has merged with and into Inspire, with Inspire surviving as a wholly owned subsidiary of Merck, effective today.
“We are excited to complete this compelling and highly complementary acquisition of Inspire,” said Beverly Lybrand, SVP and general manager, neuroscience and ophthalmology at Merck. “The successful completion of this transaction strengthens our ophthalmology business and positions us for future growth with an expanded portfolio and a best in class commercialization organization.”